HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Factors that contribute to long-term survival in patients with leukemia not in remission at allogeneic hematopoietic cell transplantation.

AbstractBACKGROUND:
There has been insufficient examination of the factors affecting long-term survival of more than 5 years in patients with leukemia that is not in remission at transplantation.
METHOD:
We retrospectively analyzed leukemia not in remission at allogeneic hematopoietic cell transplantation (allo-HCT) performed at our institution between January 1999 and July 2009. Forty-two patients with a median age of 39 years received intensified conditioning (n = 9), standard (n = 12) or reduced-intensity conditioning (n = 21) for allo-HCT. Fourteen patients received individual chemotherapy for cytoreduction during the three weeks prior to reduced-intensity conditioning. Diagnoses comprised acute leukemia (n = 29), chronic myeloid leukemia-accelerated phase (n = 2), myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) (n = 10) and plasma cell leukemia (n = 1). In those with acute leukemia, cytogenetic abnormalities were intermediate (44%) or poor (56%). The median number of blast cells in bone marrow (BM) was 26.0% (range; 0.2-100) before the start of chemotherapy for allo-HCT. Six patients had leukemic involvement of the central nervous system. Stem cell sources were related BM (7%), related peripheral blood (31%), unrelated BM (48%) and unrelated cord blood (CB) (14%).
RESULTS:
Engraftment was achieved in 33 (79%) of 42 patients. Median time to engraftment was 17 days (range: 9-32). At five years, the cumulative probabilities of acute graft-versus-host disease (GVHD) and chronic GVHD were 63% and 37%, respectively. With a median follow-up of 85 months for surviving patients, the five-year Kaplan-Meier estimates of leukemia-free survival rate and overall survival (OS) were 17% and 19%, respectively. At five years, the cumulative probability of non-relapse mortality was 38%. In the univariable analyses of the influence of pre-transplant variables on OS, poor-risk cytogenetics, number of BM blasts (>26%), MDS overt AML and CB as stem cell source were significantly associated with worse prognosis (p = .03, p = .01, p = .02 and p < .001, respectively). In addition, based on a landmark analysis at 6 months post-transplant, the five-year Kaplan-Meier estimates of OS in patients with and without prior history of chronic GVHD were 64% and 17% (p = .022), respectively.
CONCLUSION:
Graft-versus-leukemia effects possibly mediated by chronic GVHD may have played a crucial role in long-term survival in, or cure of active leukemia.
AuthorsHideo Koh, Hirohisa Nakamae, Kiyoyuki Hagihara, Takahiko Nakane, Masahiro Manabe, Yoshiki Hayashi, Mitsutaka Nishimoto, Yukari Umemoto, Mika Nakamae, Asao Hirose, Eri Inoue, Atsushi Inoue, Masahiro Yoshida, Masato Bingo, Hiroshi Okamura, Ran Aimoto, Mizuki Aimoto, Yoshiki Terada, Ki-Ryang Koh, Takahisa Yamane, Masahiko Ohsawa, Masayuki Hino
JournalJournal of experimental & clinical cancer research : CR (J Exp Clin Cancer Res) Vol. 30 Pg. 36 ( 2011) ISSN: 1756-9966 [Electronic] England
PMID21477348 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Topics
  • Adolescent
  • Adult
  • Aged
  • Disease-Free Survival
  • Female
  • Graft vs Host Disease (etiology)
  • Hematopoietic Stem Cell Transplantation (adverse effects)
  • Humans
  • Kaplan-Meier Estimate
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive (mortality, therapy)
  • Leukemia, Myeloid, Acute (mortality, therapy)
  • Leukemia, Plasma Cell (mortality, therapy)
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Myelodysplastic Syndromes (mortality, therapy)
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma (mortality, therapy)
  • Recurrence
  • Retrospective Studies
  • Transplantation, Homologous
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: